Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX-102 in the Treatment of Hyperuricemia in Patients With Gout
NCT01336686Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arhalofenate in hyperuricemia, gout, sponsored by Gilead Sciences. Started May 2011; status: completed.
02
Drugs
arhalofenate
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT01336686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01336686.